Bio-Rad Laboratories, Inc.
BIOB
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -152.34% | 114.68% | -83.33% | -304.67% | 514.74% |
| Total Depreciation and Amortization | 13.62% | 11.54% | 2.70% | 5.38% | 4.29% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 169.54% | -110.98% | 96.10% | 441.52% | -1,628.58% |
| Change in Net Operating Assets | -146.40% | 111.35% | -19.26% | -2,534.15% | 8,928.00% |
| Cash from Operations | -26.10% | 19.36% | 86.10% | 53.33% | 67.43% |
| Capital Expenditure | 21.14% | -8.04% | 14.43% | -1.54% | 8.78% |
| Sale of Property, Plant, and Equipment | -- | 0.00% | -- | -151.04% | -100.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 38.71% | 1,200.00% | 1,386.21% | -88.90% | -144.92% |
| Cash from Investing | 22.80% | -273.46% | 106.73% | -142.31% | -486.32% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | -100.00% | 50.00% | 72.85% | 15.25% |
| Issuance of Common Stock | -33.33% | -10.64% | -21.82% | -9.74% | 9.75% |
| Repurchase of Common Stock | 44.65% | -38.64% | -2,068.09% | 99.93% | -224.48% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 45.31% | -41.10% | -- | 86.91% | -260.93% |
| Foreign Exchange rate Adjustments | 114.86% | -526.32% | -166.67% | 257.46% | -218.95% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -1,300.00% | -- |
| Net Change in Cash | 488.89% | -480.08% | 13.27% | 244.01% | -93.37% |